Received Oct 21, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | OT |
pre-assessed as a medication error (unintentional) due to administration of 0.4mL of FLUBLOK to a patient, approximately 0.1mL of the vaccine shot out with no reported adverse event; Initial information received on 14-Oct-2025 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves an unknown age and unknown gender patient who received 0.4ml of Influenza Trivalent Recombinant Vaccine [FLUBLOK TIV] pre-assessed as a medication error (unintentional) and approximately 0.1ml of the vaccine shot out with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a 0.4ml dose of suspect Influenza Trivalent Recombinant Vaccine Solution for injection (lot number, strength and expiry date -unknown) via unknown route in unknown administration site for prophylactic vaccination (Immunisation) and approximately 0.1ml of the vaccine shot out with no reported adverse event (incorrect dose administered) (latency-same day). Information on the batch number was requested corresponding to the one at time of event occurrence. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.